Marimekko Corporation, Interim Report, 31 October 2025 at 8.00 a.m. EET INTERIM REPORT OF MARIMEKKO CORPORATION, 1 January–30 September 2025: Marimekko’s net sales and operating profit increased in the third quarter This release is a summary of Marimekko’s interim report for the January–September period of 2025. The complete report is attached to this release as a pdf file and it is also available on the company’s website at company.marimekko.com under Releases & publications. The third quarter in brief Mar ...

Elis announces the acquisition of Larosé in Germany Saint-Cloud, October 31, 2025 – Elis, the global leader in circular services at work, today announces the acquisition of 100% of Larosé GmbH and Mitteldeutsche Wäscherei GmbH (“Larosé”). Larosé serves the eastern part of Germany through its two laundries located in Schönebeck and Berlin. The company caters mainly to healthcare clients and offers a wide range of rental and laundry services in flat linen, workwear, and resident linen. Larosé employs around 1 ...

Schindellegi, Switzerland – 31 October 2025 Trifork Group AGCompany announcement no. 48/2025Interim Financial Report for the three and nine months ending 30 September 2025 Trifork Group reports Q3 revenue growth of 4.7% with a solid margin improvement CEO Jørn Larsen comments:“Q3 was a solid quarter marked by significant contract wins despite a continued challenging private sector business environment. We made further steady progress on our strategy to become a more product- and platform-driven business. R ...

Equinor ASA (OSE:EQNR, NYSE:EQNR) announces that Tone H. Bachke will leave her position on the Board of Directors and prioritize her executive responsibilities as EVP and CFO in SHV Holding N.V., a global company headquartered in the Netherlands. The change takes effect 31 October 2025. Contact: Nils Morten Huseby, chair of the nomination committeeEnquiries through Equinor Corporate Press Office, Sissel Rinde,+47 412 60 584 This information is subject to the disclosure requirements pursuant to Section 5-12 ...

Core Insights - Yoolax's Outdoor Lighting and Shading System has won the MUSE Design Award, highlighting the brand's commitment to innovative and intelligent design solutions that enhance outdoor living experiences [1][4][14] Company Overview - Yoolax is focused on blending design, technology, and sustainability to create products that simplify life and enrich outdoor experiences [4][14] - The brand's philosophy, "Relax your life," emphasizes the importance of comfort and connection in outdoor spaces [1][4] Product Features - The Yoolax Outdoor Shading System includes versatile options such as exterior patio sun shades, extra wide sun shades with built-in solar panels, and drop arm awnings, catering to various shading needs [6][10] - The system is designed for year-round comfort and durability, featuring a corrosion-resistant aluminum cassette and high-performance fabric available in multiple colors and openness levels [8][9] - Customization options include configurable valance designs to match different decor styles while maintaining durability [9] Smart Technology Integration - Yoolax Smart Outdoor Shades offer intuitive smart control through the Yoolax Home App, allowing users to manage settings and check battery status remotely [12] - The shades are compatible with popular smart home ecosystems, enabling voice command functionality for ease of use [12] - The solar-ready design supports eco-friendly operation, reducing electricity use while ensuring reliable performance [13] Market Positioning - The MUSE Design Award recognition positions Yoolax as a leader in the outdoor living market, emphasizing its innovative approach to creating intelligent and intuitive outdoor solutions [3][14] - Yoolax aims to transform outdoor spaces into comfortable retreats, aligning with the growing trend of outdoor areas as extensions of the home [14]

Core Points - Viking Acquisition Corp. I has priced its initial public offering (IPO) at $10.00 per unit, with a total of 20,000,000 units being offered [1] - The units will be listed on the New York Stock Exchange under the ticker symbol "VACI.U" starting October 31, 2025 [1] - Each unit consists of one Class A ordinary share and one-third of a redeemable warrant, with the whole warrant exercisable at $11.50 per share [1] - The offering is expected to close on November 3, 2025, subject to customary closing conditions [2] Company Overview - Viking Acquisition Corp. I is a blank check company aimed at merging, acquiring, or reorganizing with one or more businesses, without limitations on industry or geographic region [5]

Core Insights - Lendlease Global Commercial REIT reported strong operational performance with a portfolio committed occupancy of 95.0% as of September 30, 2025, and a positive retail rental reversion of 8.9% [4][6][10] - The divestment of Jem office is nearing completion, expected by November 12, 2025, with a projected disposal gain of approximately S$8.9 million for Unitholders [3][10] - The company has been recognized for its sustainability efforts, being awarded the Regional Sector Leader in Retail Asia (Listed) by GRESB 2025 and included in the iEdge Singapore Next 50 Index [11][12] Operational Performance - The retail portfolio's occupancy rate exceeded 99%, while the Milan office portfolio occupancy increased to 88.5% from 81.6% [4] - Tenant retention was reported at 52.2%, with a notable increase to 72.9% when excluding the exit of Cathay Cineplexes [6] - Visitation improved by 7.7% year-on-year, although tenant sales dipped by 0.8% [7] Capital Management - Lendlease REIT refinanced S$115.5 million in loans, with gross borrowings at S$1,668.9 million and a weighted average debt maturity of 2.6 years [8] - Approximately 68% of borrowings were hedged to fixed rates, with the weighted average cost of debt improving to 3.09% per annum [9][10] - The interest coverage ratio was reported at 1.6 times based on the last financial results [9] Awards and Recognition - Inclusion in the iEdge Singapore Next 50 Index has doubled the average daily trading volume to approximately 10 million units [11] - Lendlease REIT achieved a 5 Star rating in the GRESB assessment for its ESG performance, marking the sixth consecutive year as Regional Sector Leader [12][13]

EFFINGHAM, Ill., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Midland States Bancorp, Inc. (Nasdaq: MSBI) (the “Company”) today reported net income available to common shareholders of $5.3 million, or $0.24 per diluted share, for the third quarter of 2025, compared to net income available to common shareholders of $9.8 million, or $0.44 per diluted share, for the second quarter of 2025. This also compares to net income of $18.2 million, or $0.83 per diluted share, for the third quarter of 2024. 2025 Third Quarter Resu ...

ANCHORAGE, Alaska, Oct. 30, 2025 (GLOBE NEWSWIRE) -- At the Board of Directors meeting held Oct. 30, 2025, First National Bank Alaska (OTCQX:FBAK) declared a cash dividend of $4.00 per share for shareholders of record as of Dec. 1, 2025, payable on Dec. 15, 2025. At the same meeting, the Board declared a special cash dividend of $4.00 per share for shareholders of record as of Dec. 1, 2025, payable on Dec. 19, 2025. CONTACT: Denise Brown RobinsonSecretary to the Board of Directors907-777-3409 ...

Core Insights - InnoCare Pharma has initiated a clinical trial for its novel B7-H3 targeted antibody-drug conjugate (ADC), ICP-B794, marking a significant step in cancer treatment development in China [1][2]. Company Overview - InnoCare Pharma is a biopharmaceutical company focused on developing treatments for cancer and autoimmune diseases, with a commitment to addressing unmet medical needs both in China and globally [6]. Product Development - ICP-B794 is designed as a humanized anti-B7-H3 monoclonal antibody linked to a potent payload, ensuring targeted delivery to tumor cells while reducing off-target effects [2]. - The ADC has shown superior anti-tumor activity in animal models compared to other ADCs, demonstrating significant efficacy even against large tumors [2]. Market Potential - Currently, there are no approved therapies targeting B7-H3 globally, making it a promising target due to its high expression in various solid tumors [3]. - The ADC platform developed by InnoCare aims to tackle hard-to-treat cancers, potentially offering improved safety and efficacy profiles for cancer patients [5]. Leadership Perspective - Dr. Jasmine Cui, co-founder and CEO, emphasized the potential of ICP-B794 to provide precise treatment options for cancer patients and the company's commitment to expanding its ADC portfolio [4].